2. Search Result
Search Result
Results for "

GSPT1

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153803
    GBD-9

    		PROTACs Molecular Glues Btk Cancer
    GBD-9 is a double-mechanism degrader that efficiently degrades BTK and GSPT1 by recruiting the E3 ligase cereblon (CRBN). GBD-9 acts both as a PROTAC molecule to induce the degradation of BTK and as a molecular glue to degrade GSPT1. GBD-9 effectively inhibits cancer cell growth [1].
    GBD-9
  • HY-156747
    GSPT1 degrader-2

    		Others Cancer
    GSPT1 degrader-2 is a potent GSPT1 degrader [1].
    <em>GSPT1</em> degrader-2
  • HY-155552
    GSPT1 degrader-1

    		Apoptosis Cancer
    GSPT1 degrader-1 (compound 9q) is a potent degrader of G1 to S phase transition 1 (GSPT1) via ubiquitin-proteasome system. GSPT1 degrader-1 also induces cell G0/G1 phase arrest and apoptosis [1].
    <em>GSPT1</em> degrader-<em>1</em>
  • HY-RS05868
    GSPT1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    GSPT1 Human Pre-designed siRNA Set A contains three designed siRNAs for GSPT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    GSPT1 Human Pre-designed siRNA Set A
    GSPT1 Human Pre-designed siRNA Set A
  • HY-157426
    GSPT1 degrader-3

    		Epigenetic Reader Domain PROTACs Cancer
    GSPT1 degrader-3 (Pro-2) is a CRBN-based PROTAC degrader for BRD, with a DC50 of 21.1 nM (4h) [1].
    <em>GSPT1</em> degrader-3
  • HY-150616
    SJPYT-195

    		Ligands for E3 Ligase Cancer
    SJPYT-195 is a cytotoxic GSPT1 degrader and can be used for PROTAC synthesis [1].
    SJPYT-195
  • HY-132199
    SJ6986

    		Others Cancer
    SJ6986 is a potent, selective and orally active GSPT1/2 degrader, with a DC50 of 2.1 nM (Dmax 99%) for GSPT1 [1].
    SJ6986
  • HY-130800
    Eragidomide
    1 Publications Verification

    CC-90009

    		 Ligands for E3 Ligase Molecular Glues Apoptosis Inflammation/Immunology Cancer
    Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the CRL4 CRBN to selectively target GSPT1 for ubiquitination and proteasomal degradation [1] .
    Eragidomide
  • HY-147158
    ZXH-1-161

    		Molecular Glues Ligands for E3 Ligase Cancer
    ZXH-1-161 is a potent cereblon (CRBN) modulator with an IC50 value of 39 nM in MM1.S wild type cells. ZXH-1-161 has selective degradation activity towards GSPT1. ZXH-1-161 can be used for researching multiple myeloma [1].
    ZXH-<em>1</em>-161
  • HY-136688
    MI-389

    		PROTACs Cancer
    MI-389 is a PROTAC translation termination factor GSPT1 degrader. MI-389 disrupts a target that is a shared dependency in different AML and ALL cell lines, and that MI-389 action is dependent on the CRL4 CRBN E3 ligase [1].
    MI-389
  • HY-101488
    CC-885
    10+ Cited Publications

    		 Molecular Glues Ligands for E3 Ligase Cancer
    CC-885 is a cereblon (CRBN) modulator with potent anti-tumour activity. CC-885 is also a known degrader of GSPT1, inhibiting protein translation.
    CC-885
  • HY-150259
    MDEG-541

    		PROTACs c-Myc Cancer
    MDEG-541 is a potent MYC-MAX degrader. MDEG-541 is a PROTAC that based on the MYC-MAX dimerization inhibitor 10058-F4 derivative 28RH and Thalidomide (HY-14658). MDEG-541 shows antiproliferative activity. MDEG-541 decreases the expression of GSPT1, MYC, GSPT2, PLK1 protein [1].
    MDEG-541
  • HY-130122
    MG-277

    		Molecular Glues PROTACs Apoptosis Cancer
    MG-277, a molecular glue degrader, effectively induces degradation of a translation termination factor based on Cereblon E3 ligand, GSPT1, with a DC50 of 1.3 nM. MG-277 potently inhibits tumor cell growth in a p53-independent manner, with IC50s of 3.5 nM for RS4;11 cells and 3.4 nM for p53 mutant RS4;11/IRMI-2 cells, respectively. Anticancer activity [1].
    MG-277
  • HY-143435
    AG6033

    		Apoptosis Cancer
    AG6033 is a potential novel CRBN modulator. AG6033 suppresses various tumor cells by modulating the interactions between CRBN and various antitumor target proteins. AG6033 can cause GSPT1 and IKZF1 degradation. AG6033 induces CRBN-dependent cytotoxic effect [1].
    AG6033
  • HY-151902
    SJ988497

    		PROTACs JAK Cancer
    SJ988497 is a PROTAC JAK2 degrader. SJ988497 potently inhibits CRLF2-rearranged (CRLF2r) cell proliferation and degrades the CRBN neosubstrate GSPT1. SJ988497 consists of a Ruxolitinib (HY-50856) derivative, linker, and CRBN ligand Pomalidomide. SJ988497 can be used in the research of acute lymphoblastic leukemia (ALL) [1].
    SJ988497
  • HY-148837
    c-Myc inhibitor 7

    		c-Myc Casein Kinase Infection Cardiovascular Disease Cancer
    c-Myc inhibitor 7 is a c-Myc inhibitor and a multiple target protein degrader. c-Myc inhibitor 7 effective degrades c-MYC, CK1α, GSPT1 and IKZF1/2/3 proteins in a variety of tumor cells. c-Myc inhibitor 7 can be used for c-Myc high expression related disease research, such as cancer, cardiovascular and cerebrovascular diseases, and viral infection [1].
    c-Myc inhibitor 7
  • HY-153356
    MRT-2359

    		Apoptosis Cancer
    MRT-2359 is a potent, orally active and selective GSPT1 depressant (IC50: >30 nM and <300 nM) that specifically induces apoptosis dependent on protein translation. MRT-2359 exhibits significant and preferred anti-proliferative activity in a variety of cancer cell lines, especially MYC-driven cell lines, such as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) with high expression of N-Myc or L-Myc. MRT-2359 inhibits the growth of drug-resistant NSCLC and SCLC cells, making it suitable for cancer research [1] .
    MRT-2359

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: